Y-mabs Therapeutics

Provider of antibodies-based products targeting GD2 and B7H3 tumor antigens.

placeNew York City, New York, United States calendar_todayFounded 2014 groups100 employees language ymabs.com

Innovation

12 patent families (1 granted) — focus: Chemistry & metallurgy, Human necessities, Physics & computing; filing pace slowing. Cited 253 times.

YearFilings
20181
20191
20201
20216
20226
20236
20245
20254

Social engagement

Social engagement: 11K social following, 9 posts in the last 12 months — above the industry median.

Investor mix

5 investors on record; 1 has since exited.

Investor typeCountShare
Venture capital240%
Private equity240%
Other / undisclosed120%

Recent activity

29 Oct 2025
Event
MM+M Media Summit
24 Sep 2025
Event
APHON 2025 Annual Conference
16 Sep 2025
Event
CoG Fall Meeting
Coming soon